RT Journal Article
SR Electronic
T1 Identification of an Oleanane-type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP mol.117.109900
DO 10.1124/mol.117.109900
A1 Yi Lu
A1 Weili Zheng
A1 Shengchen Lin
A1 Fusheng Guo
A1 Yanlin Zhu
A1 Yijuan Wei
A1 Xi Liu
A1 Shikai Jin
A1 Lihua Jin
A1 Yong Li
YR 2017
UL http://molpharm.aspetjournals.org/content/early/2017/11/21/mol.117.109900.abstract
AB Farnesoid X receptor (FXR) and G-protein-coupled BA receptor 1 (GPBAR1) are two important bile acid (BA) receptors. As a non-BAs drug template for GPBAR1, none of the natural oleanane-type triterpene has been reported as FXR ligands, despite that FXR and GPBAR1 have similar binding pockets for BAs. Here, we report the natural triterpene hedragonic acid that has been isolated from the stem and root of Celastrus orbiculatus Thunb. (COT) as an effective agonist for FXR. Both biochemical AlphaScreen and cell-based reporter assays showed that hedragonic acid regulated the transcriptional activity of FXR. CD spectroscopy further suggested the conformational changes of FXR upon the binding of hedragonic acid. Interestingly, the crystal structure of hedragonic acid-bound FXR revealed a unique binding mode with hedragonic acid occupying a novel binding pocket different from the classical binding position. The structural comparison between hedragonic acid-bound FXR and oleanolic acid-bound GPBAR1 explained the molecular basis for the selectivity of oleanane-type triterpenes for FXR. Moreover, hedragonic acid treatment protected mice from liver injury induced by overdose acetaminophen and decreased hepatic inflammatory responses in an FXR-dependent manner, suggesting that hedragonic acid might be one of the major components of COT for its multifunctional pharmaceutical uses. In conclusion, our results have provided novel structure templates for drug design based on natural triterpenes by targeting FXR and/or GPBAR1 with pharmaceutical values.